PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient

Publisher： Karger

E-ISSN： 2296-5262|33|1-2|57-59

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.1-2, 2010-01, pp. : 57-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report

By  

Case Reports in Oncology, Vol. 2, Iss. 1, 2009-04 ,pp. : 72-76

Karger

Access to resources Recommend Favorite

Metastatic Prostate Cancer in an Asymptomatic Patient with an Initial Prostate-Specific Antigen (PSA) Serum Concentration of 21,380 ng/ml

By  

Oncology Research and Treatment, Vol. 33, Iss. 3, 2010-02 ,pp. : 110-112

Karger

Access to resources Recommend Favorite

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 300-305

Karger

Access to resources Recommend Favorite

PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report

By  

Case Reports in Oncology, Vol. 5, Iss. 1, 2012-04 ,pp. : 181-186

Karger

Access to resources Recommend Favorite

Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 4, 2016-03 ,pp. : 217-220

Karger

Access to resources Recommend Favorite